GlassScriptPhysician profile
Moustafa S Ahmed
NPI 1225182751
$9,799.98
in general payments reported to CMS, 2019-2025
38 companies · $892 in 2025
The $892 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,369 · 2020: $1,370 · 2021: $1,657 · 2022: $1,480 · 2023: $1,777 · 2024: $1,254 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,923.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,025.96 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,418.85 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Gilead Sciences, INC. | $752.13 | 2019-2025 | |
| Pfizer INC. | $610.11 | 2019-2025 | |
| Celgene Corporation | $598.80 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $539.75 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $447.97 | 2019-2024 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $386.64 | 2019-2025 | Entyvio |
| Allergan, INC. | $329.04 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $254.61 | 2019-2024 | Dificid, Zinplava |
| Genzyme Corporation | $234.80 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $225.87 | 2020-2023 | Linzess |
| Braintree Laboratories, INC. | $202.87 | 2019-2025 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $186.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $180.09 | 2019-2023 | Stelara, Remicade, Simponi |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $171.13 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $149.94 | 2020-2023 | Ocaliva |
| Ardelyx, INC. | $132.33 | 2022-2025 | Ibsrela |
| Exact Sciences Corporation | $117.77 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Saluda Medical Americas, INC. | $112.73 | 2025 | Evoke |
| Echosens North America, INC. | $102.36 | 2023-2024 | Fibroscan |
| Shionogi INC | $86.40 | 2019-2020 | |
| Evoke Pharma, INC. | $81.87 | 2020-2025 | Gimoti |
| Lilly USA, LLC | $62.17 | 2024-2025 | Omvoh |
| Vivus LLC | $60.82 | 2019-2020 | |
| Abbott Laboratories | $48.88 | 2025 | Proclaim |
| Novo Nordisk INC | $44.62 | 2025 | Wegovy |
| Redhill Biopharma INC. | $43.86 | 2021-2022 | |
| Qol Medical, LLC | $23.03 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.94 | 2022 | |
| Organon LLC | $22.87 | 2023 | |
| Boston Scientific Corporation | $21.26 | 2019 | |
| Daiichi Sankyo INC. | $20.45 | 2019 | |
| Aimmune Therapeutics, INC. | $19.41 | 2025 | Zenpep |
| Sun Pharmaceutical Industries INC. | $18.96 | 2021 | |
| Capsovision, INC. | $14.95 | 2023 | Capsocam Plus |
| Regeneron Healthcare Solutions, INC. | $14.38 | 2022 | |
| Fresenius Kabi USA, LLC | $13.11 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moustafa Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.